Highlights Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
2.33 ^USD	-2.92%		-2.10%	+0.43%

05-09	Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M	05-09	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q4 Revenue $10.7M, vs. Street Est of $14.8M	02-28	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Mersana Therapeutics, Inc. Announces Business Updates	01-05	CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Mersana Therapeutics, Inc. Announces FDA Has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056	23-10-31	CI
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q2 Revenue $10.7M	23-08-08	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization	23-07-27	CI
Mersana Therapeutics Says FDA Issues Partial Clinical Hold on Enrollment in Ovarian Cancer Drug Trials; Shares Plunge	23-06-15	MT
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials	23-06-15	CI
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $7.8M, vs. Street Est of $18.3M	23-05-09	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Mersana Therapeutics, Inc. Announces Phase 1 Trial of XMT-2056 Has Been Placed on Clinical Hold by the U.S. Food and Drug Administration	23-03-13	CI
Mersana Therapeutics Q4 Loss Narrows, Revenue Climbs	23-02-28	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Mersana Therapeutics, Inc. Initiates Expansion Portion of Upgrade-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer	23-02-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Highlights

Filters